Browse the evidence

GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.

Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.

Herbal medicine interventions for obesity exhibit pleiotropic mechanisms, including thermogenesis, inhibition of pancreatic lipase, reduced food intake, and increased lipolysis, mediated by secondary metabolites like flavonoids and saponins.

Herbal medicines for obesity work through multiple pathways, such as boosting metabolism (thermogenesis), blocking fat absorption (lipase inhibition), and reducing appetite. They are not single-target drugs but complex mixtures that may offer a safer profile than prescription weight-loss drugs, though they still require careful monitoring.

Targeting thermogenesis via β3-adrenergic receptor (β3-AR) activation can increase energy expenditure and promote brown adipose tissue (BAT) activity, offering a complementary mechanism to GLP-1 agonists for obesity management.

Research is actively exploring medications that activate brown fat (thermogenesis) to burn more calories. While not yet standard care, these drugs (like β3-agonists) work by increasing energy expenditure. They may eventually be used alongside GLP-1 medications to overcome weight loss plateaus. Current options are limited by side effects, but newer, more selective drugs are showing promise in clinical trials.

GLP-1 receptor agonists, particularly semaglutide and tirzepatide, are associated with an increased risk of non-scarring hair loss (telogen effluvium and androgenetic alopecia), primarily driven by rapid weight loss and nutritional deficits rather than direct drug toxicity.

If you are using semaglutide or tirzepatide and notice hair shedding, it is likely due to rapid weight loss or nutritional deficits rather than permanent drug damage. Ensure adequate protein and micronutrient intake (iron, zinc) and consider slowing dose escalation. The risk is highest with these specific drugs and in females, but often stabilizes as weight loss plateaus.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.

Carbohydrate reduction leads to a significant decrease in Alanine Aminotransferase (ALT) levels, indicating improved liver function, while HDL cholesterol may show a small decline.

Your liver function is likely to improve, as shown by a significant drop in ALT levels. However, be aware that HDL ('good') cholesterol may decrease slightly. This is a common finding with carbohydrate reduction and should be monitored by your doctor.

Eliminating in vivo digestibility requirements (PDCAAS) for protein content claims and relying solely on protein amount per serving aligns food labeling with dietary guidelines, promotes plant-based food consumption, and improves public health outcomes.

If you are eating enough total protein from varied sources, you do not need to worry about complex protein quality scores on labels. Focus on choosing plant-based protein sources (beans, lentils, soy) which are often disadvantaged by current labeling rules. This change helps you make healthier choices that lower saturated fat and increase fiber, supporting long-term health without needing to track complex metrics.

Higher body mass index (BMI) is associated with lower self-reported physical functioning and overall health-related quality of life (HRQoL) in people with overweight or obesity.

If you have overweight or obesity, your daily physical ability and general health perception are likely lower than average, and this tends to get worse as your BMI increases. This is a measurable health burden, not just a cosmetic issue, and addressing weight may improve your physical functioning.

The presence of cardiovascular (CV) or metabolic comorbidities significantly reduces health-related quality of life (HRQoL) and work productivity in people with overweight or obesity, often more so than BMI alone.

Having overweight or obesity is only part of the story. If you also have heart or metabolic conditions (like diabetes), your quality of life and work productivity are likely significantly lower than someone with the same BMI but no comorbidities. Treating these specific conditions is crucial for your well-being.

People with overweight or obesity and metabolic comorbidities experience significantly higher work impairment (activity impairment and presenteeism) compared to those without such comorbidities.

If you have overweight or obesity and metabolic conditions like diabetes, your work productivity is likely significantly lower than someone with the same BMI but no metabolic issues. This is due to reduced activity levels and effectiveness at work, which are key targets for treatment.

Current interventions, including calorie restriction, physical activity, and pharmacological treatment, show promise in combating obesity, but long-term efficacy and safety need further establishment.

There is no single magic bullet for obesity. The most promising approach combines lifestyle changes (diet and exercise) with medical treatments if necessary. However, long-term success is not guaranteed, and ongoing management is likely required.

Tirzepatide, a dual GLP-1/GIP agonist, may enhance metabolic efficiency and endurance performance by optimizing fat oxidation, delaying glycogen depletion, and improving mitochondrial function.

If you are an endurance athlete using tirzepatide, you may experience improved metabolic efficiency. The drug can help spare glycogen stores and enhance mitochondrial function, potentially supporting longer exercise durations. However, monitor for signs of hypoglycemia during high-intensity training and ensure adequate carbohydrate intake to counteract potential energy deficits.

Tirzepatide is a broadly acceptable and preferred long-term treatment for comorbid obesity and obstructive sleep apnea (COBOSA) by patients, offering efficacy comparable to CPAP with different adherence profiles.

If you have obesity and sleep apnea, tirzepatide is a valid, once-weekly treatment option that many patients prefer over CPAP. Discuss with your doctor if it's right for you, considering factors like cost, side effects, and your preference for injections vs. devices.

Reallocating 30 minutes of daily sedentary time to moderate-to-vigorous physical activity (MVPA) in young, healthy, active adults increases daily energy intake by approximately 113–120 kcal and alters appetite hormones (higher fasting ghrelin, lower postprandial PYY) to compensate for energy expenditure, without affecting hedonic food reward traits.

If you are already active and healthy, increasing your moderate-to-vigorous exercise by 30 minutes a day will likely make you hungrier and cause you to eat about 120 more calories. This is your body's natural way of balancing energy. To manage weight, you must consciously account for this increased intake rather than assuming exercise alone creates a deficit. If your goal is performance, use this hunger to fuel your activity.

Referral to a specialized weight management clinic alongside incretin-based therapy does not significantly improve early glycemic (A1c) or lipid (LDL) outcomes compared to standard diabetes care alone, but increases weight loss only when patients attend 4 or more visits.

If you are starting a GLP-1 or similar medication, standard diabetes care provides similar early blood sugar and cholesterol benefits as specialized weight management clinics. However, to maximize weight loss, you likely need to attend 4 or more specialized weight management visits. Simply getting the prescription and seeing the specialist once may result in less weight loss than standard care alone.

Second-generation incretin-based therapies (semaglutide, tirzepatide) increase the risk of micronutrient deficiencies and related complications, primarily through reduced dietary intake and altered food selection, with real-world data showing a 22.4% incidence of recorded nutritional deficiencies at 12 months.

If you are taking semaglutide or tirzepatide, your reduced food intake may lead to micronutrient gaps. Prioritize nutrient-dense foods (vegetables, lean proteins, dairy) and consider discussing baseline testing (Vitamin D, B12, Iron) with your doctor, especially if you experience GI side effects or rapid weight loss.

Incretin-based therapies alter dietary patterns by reducing cravings for high-fat and sugary foods, which may displace micronutrient-dense food groups if not actively managed.

You may naturally crave less junk food. Use this opportunity to fill your plate with vegetables and lean proteins to ensure you get enough vitamins and minerals.

GLP-1 receptor agonist use during radiation therapy causes rapid weight loss and anatomic changes that compromise immobilization reproducibility and dosimetric accuracy, necessitating adaptive radiotherapy or temporary holding of the medication.

If you are taking GLP-1 drugs (like Ozempic or Wegovy) while getting radiation, tell your radiation team immediately. These drugs cause weight loss and stomach changes that can make your radiation treatment less accurate. Your team may ask you to pause the drug or scan you more often to adjust the treatment plan. This is to keep you safe and ensure the radiation hits the tumor correctly.

Dose de-escalation (tapering) or low-dose maintenance therapy may modestly limit the rate and magnitude of weight regain compared to abrupt cessation, but robust randomized evidence is currently lacking.

If you want to stop your incretin medication, talk to your doctor about tapering the dose or extending the time between injections rather than stopping abruptly. While this might help slow down weight regain, it is not a guaranteed solution, and you should expect some regain. Continuing at a lower dose is generally better than stopping completely.

Nutrient-stimulated hormone (NuSH) therapies, including GLP-1 and dual/tri-agonists, produce significant weight loss and cardiometabolic improvements in real-world settings, though response heterogeneity, high discontinuation rates, and post-cessation weight regain remain unresolved challenges.

NuSH therapies (like semaglutide or tirzepatide) are highly effective for significant weight loss and metabolic health in real-world use, but they are not magic bullets. Expect a significant portion of people to not respond well, experience side effects leading to stopping the drug, or regain weight after stopping. Success requires individualized dosing, lifestyle support, and an understanding that obesity management is often a long-term commitment rather than a quick fix.

β-hydroxy-β-methylbutyrate (HMB, 3 g/day) has conditional utility for muscle hypertrophy, showing benefits primarily during high training stress or caloric deficits, but is largely neutral in well-fed, resistance-trained individuals.

If you are dieting or doing extremely high-volume training, 3g of HMB daily might help preserve muscle. If you are eating well and training normally, HMB is likely a waste of money as it shows no benefit in this group.

Adjunct supplements (omega-3 fatty acids, citrulline, collagen) facilitate training tolerance, recovery, or connective-tissue adaptation but do not directly drive muscle hypertrophy.

These supplements can help you train better, recover faster, or keep your tendons healthy, but they won't build muscle directly. Focus on protein, creatine, and training first; these are optional extras for specific needs.

Systematic evaluation of nutrition claims on Instagram targeting women reveals widespread misinformation and low scientific rigor, necessitating evidence-based digital platforms to improve health literacy.

If you are a woman seeking nutrition advice on Instagram, be aware that many posts lack scientific rigor. Use platforms like NutriWomen that systematically evaluate these claims using scientific methods (like AMSTAR-2 and GRADE) to provide you with trustworthy, accessible summaries. Do not rely solely on influencer posts without checking for evidence-based backing.

In individuals with MASLD undergoing ~30% caloric restriction, resistance training preserves skeletal muscle mass and improves functional strength, whereas adding whey protein supplementation (1.5 g/kg/day) provides no additional benefit over resistance training alone (0.8 g/kg/day).

If you have MASLD and are cutting calories significantly, focus on resistance training and getting adequate protein (around 0.8 g/kg/day). Adding extra whey protein (up to 1.5 g/kg/day) does not provide extra muscle or strength benefits in this specific scenario. The energy deficit blunts the potential synergy of high protein and exercise.